查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600981

胰岛素市场：按药物、类型和应用分类 - 2025-2030 年全球预测

Insulin Market by Drug (Biologic, Biosimilar), Type (Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年胰岛素市值为436.4亿美元，预计2024年将达467.6亿美元，复合年增长率为7.63%，预计到2030年将达到730.3亿美元。

胰岛素是糖尿病管理的重要激素，也是治疗第 1 型和第 2 型糖尿病的中流砥柱。胰岛素市场范围围绕着药品、生物相似药和先进的输送系统。全球糖尿病盛行率上升、生活方式改变和肥胖率上升推动了对胰岛素的需求。主要应用包括注射胰岛素製剂、胰岛素帮浦和新的非侵入性输送机制。胰岛素具有广泛的最终用途，包括医院、诊所和居家照护，为不同的患者群体提供服务。

主要市场统计
基准年[2023] 436.4亿美元
预测年份 [2024] 467.6亿美元
预测年份 [2030] 730.3亿美元
复合年增长率（%） 7.63%

市场成长的关键因素包括胰岛素输送系统的技术进步、政府糖尿病管理倡议的增加以及新兴国家医疗保健基础设施的加强。人们对糖尿病治疗和胰岛素治疗益处的认识不断提高，进一步刺激了市场扩张。吸入式胰岛素和智慧胰岛素笔等创新输送方法的开发以及使用人工智慧的个人化胰岛素治疗存在潜在机会。公司可以利用这些趋势，透过投资研发来开发易于使用且高效的胰岛素输送解决方案，并与医疗保健提供者合作以改善患者的治疗效果。

然而，市场面临着胰岛素成本高、法规结构严格以及口服药物和生活方式管理计划等替代糖尿病治疗方法的竞争等挑战。它们也有局限性，包括潜在的副作用以及需要持续监测和剂量调整。需要开拓创新领域，包括生物相似药产品、人工胰腺系统的进步以及考虑用于长期糖尿病管理的基因治疗。

胰岛素市场是一个充满活力的市场，具有巨大的成长潜力。公司应专注于技术整合、具有成本效益的解决方案以及扩大服务不足地区获得胰岛素的机会。随着医疗保健领域的发展，利用疾病管理的预测分析以及以患者为中心的方法可以在胰岛素市场上提供显着的竞争优势并推动可持续的业务成长。

市场动态：揭示快速发展的胰岛素市场的关键市场洞察

供需的动态交互作用正在改变胰岛素市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 随着老年人口的增加，糖尿病和肥胖症的盛行率不断增加
    • 胰岛素输送系统的快速发展
    • 已开发国家胰岛素产品优惠报销政策
  • 市场限制因素
    • 与胰岛素药物相关的高成本
  • 市场机会
    • 投资胰岛素开发研发活动的可能性
    • 相容生物相似药胰岛素产品的核准增加
  • 市场挑战
    • 复杂的监管环境与病患照护连续性问题

波特五力：驾驭胰岛素市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解胰岛素市场的外部影响

外部宏观环境因素在塑造胰岛素市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解胰岛素市场的竞争状况

对胰岛素市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵胰岛素市场供应商绩效评估

FPNV定位矩阵是评估胰岛素市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分了供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着人口老化的加剧，糖尿病和肥胖症的发生率上升
      • 胰岛素输送系统的快速发展
      • 已开发国家胰岛素产品优惠报销政策
    • 抑制因素
      • 与胰岛素药物相关的高成本
    • 机会
      • 胰岛素研发活动的潜在投资
      • 相容生物相似药胰岛素产品的核准增加
    • 任务
      • 复杂的监管环境以及患者遵守治疗计划的问题
  • 市场区隔分析
    • 药品：安全、有效、创新的生物药品的重要用途
    • 类型：长效胰岛素在较长时间内覆盖基础胰岛素。
    • 应用：第1型糖尿病患者大量使用胰岛素，需持续监测并及时给予胰岛素。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按药物分類的胰岛素市场

  • 生物
  • 生物相似药

第七章胰岛素市场：依类型

  • 中效胰岛素
  • 长效胰岛素
  • 预混合料胰岛素
  • 速效胰岛素
  • 短效胰岛素

第八章胰岛素市场：依应用分类

  • 1型糖尿病
  • 2型糖尿病

第九章美洲胰岛素市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太胰岛素市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲胰岛素市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 赛诺菲考虑在德国工厂投资 16 亿美元以提高产量
    • Arecor 和Medtronic Diabetes 合作开发植入式帮浦中的耐热胰岛素
    • Eris Lifesciences 收购 Biocon Biologics 的印度品牌製剂业务
    • 胰岛素製造商Genesis投资500-6000万美元在海得拉巴建工厂
    • 海湾製药工业公司「Julfar」与 Sunshine Lake Pharma 签署突破性协议，成为中东和北非地区生物相似药製造的先驱
    • 赛诺菲在印度推出新的长效药物
    • 加州和製药公司合作生产负担得起的胰岛素
    • 诺和诺德为印度患者推出每週胰岛素治疗
    • ADOCIA宣布与合作伙伴通化东宝合作ChaperoneLispro期试验取得成功
    • Glenmark在印度推出第二型糖尿病及高抗药性药物，股价大涨
    • 礼来公司和 EVA Pharma 宣布建立合作伙伴关係，以加强非洲可持续获得负担得起的胰岛素
    • 诺和诺德推出 Tresiba 类似物非品牌生物製药胰岛素，以扩大患者的购买选择
    • Optum 和赛诺菲合作为未投保者提供低成本胰岛素

公司名单

  • ADOCIA
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Biocon Limited
  • Bioton SA
  • CardioVends
  • Eli Lilly and Company
  • Eva Pharma
  • GeneSys Biologics
  • Glenmark Pharmaceuticals Ltd.
  • Gulf Pharmaceutical Industries（Julphar）
  • MannKind Corporation
  • Merck & Co., Inc.
  • MJ Biopharm Pvt. Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Viatris Inc.
  • Wockhardt Limited
  • Zealand Pharma A/S
Product Code: MRR-03548A2B9FF7

The Insulin Market was valued at USD 43.64 billion in 2023, expected to reach USD 46.76 billion in 2024, and is projected to grow at a CAGR of 7.63%, to USD 73.03 billion by 2030.

Insulin, a crucial hormone for diabetes management, is central to both Type 1 and Type 2 diabetes treatments. The market scope for insulin revolves around pharmaceuticals, biosimilars, and advanced delivery systems. The necessity of insulin is driven by the rising global prevalence of diabetes, lifestyle changes, and increasing obesity rates. Major applications include injectable insulin formulations, insulin pumps, and emerging non-invasive delivery mechanisms. Insulin's end-use scope spans hospitals, clinics, and homecare settings, catering to diverse patient demographics.

KEY MARKET STATISTICS
Base Year [2023] USD 43.64 billion
Estimated Year [2024] USD 46.76 billion
Forecast Year [2030] USD 73.03 billion
CAGR (%) 7.63%

Key market growth influencers include technological advancements in insulin delivery systems, increased government initiatives for diabetes management, and enhanced healthcare infrastructure in emerging economies. Rising awareness about diabetes care and the advantages of insulin therapy further stimulate market expansion. Potential opportunities lie in developing innovative delivery methods, like inhalable insulin or smart insulin pens, and leveraging artificial intelligence for personalized insulin therapy. Companies can capitalize on these trends by investing in research and development to create user-friendly, efficient insulin delivery solutions and collaborate with healthcare providers to improve patient outcomes.

However, the market faces challenges such as high insulin costs, stringent regulatory frameworks, and competition from alternative diabetes treatments like oral medications and lifestyle management programs. Limitations include potential side effects and the necessity for constant monitoring and dose adjustments. Innovative areas ripe for exploration include biosimilar insulin products, advancements in artificial pancreas systems, and exploration of gene therapy for long-term diabetes management.

The insulin market presents a dynamic environment with substantial growth potential. Companies should focus on technological integration, cost-effective solutions, and expanding access to insulin in under-served regions. As the healthcare landscape evolves, aligning with patient-centric approaches and utilizing predictive analytics for disease management can offer significant competitive advantages and foster sustainable business growth in the insulin market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Insulin Market

The Insulin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of diabetes and obesity with increasing geriatric population
    • Rapid development in insulin delivery systems
    • Favorable reimbursement policies for insulin products in developed countries
  • Market Restraints
    • High cost associated with insulin drugs
  • Market Opportunities
    • Potential investments in R&D activities for insulin development
    • Rising approvals for interchangeable biosimilar insulin products
  • Market Challenges
    • Complex regulatory landscape and problems related to patient adherence to treatment regimens

Porter's Five Forces: A Strategic Tool for Navigating the Insulin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Insulin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Insulin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Insulin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Insulin Market

A detailed market share analysis in the Insulin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Insulin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Insulin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Insulin Market, highlighting leading vendors and their innovative profiles. These include ADOCIA, AstraZeneca PLC, Baxter International, Inc., Biocon Limited, Bioton S.A., CardioVends, Eli Lilly and Company, Eva Pharma, GeneSys Biologics, Glenmark Pharmaceuticals Ltd., Gulf Pharmaceutical Industries (Julphar), MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., Wockhardt Limited, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Insulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Biologic and Biosimilar.
  • Based on Type, market is studied across Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin, Rapid-acting Insulin, and Short-acting Insulin.
  • Based on Application, market is studied across Type I Diabetes and Type II Diabetes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of diabetes and obesity with increasing geriatric population
      • 5.1.1.2. Rapid development in insulin delivery systems
      • 5.1.1.3. Favorable reimbursement policies for insulin products in developed countries
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with insulin drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Potential investments in R&D activities for insulin development
      • 5.1.3.2. Rising approvals for interchangeable biosimilar insulin products
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscape and problems related to patient adherence to treatment regimens
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug: Significant use of biologic drugs due to having safety, efficacy, and innovative features
    • 5.2.2. Type: Long-acting insulins provide basal coverage for an extended duration
    • 5.2.3. Application: Extensive use of insulin by type I diabetic patients requires constant monitoring and timely administration of insulin
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Insulin Market, by Drug

  • 6.1. Introduction
  • 6.2. Biologic
  • 6.3. Biosimilar

7. Insulin Market, by Type

  • 7.1. Introduction
  • 7.2. Intermediate-acting Insulin
  • 7.3. Long-acting Insulin
  • 7.4. Premixed Insulin
  • 7.5. Rapid-acting Insulin
  • 7.6. Short-acting Insulin

8. Insulin Market, by Application

  • 8.1. Introduction
  • 8.2. Type I Diabetes
  • 8.3. Type II Diabetes

9. Americas Insulin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Insulin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Insulin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Sanofi Eyes USD 1.6 Billion Investment in German Insulin Facility to Boost Production
    • 12.3.2. Arecor and Medtronic Diabetes Collaborate to Develop Thermostable Insulin for Implantable Pumps
    • 12.3.3. Eris Lifesciences Acquires India branded Formulation Business of Biocon Biologics
    • 12.3.4. Insulin Maker GeneSys to Invest USD 50-60 MN to Set Up Plant in Hyderabad
    • 12.3.5. Gulf Pharmaceutical Industries 'Julphar' Signs Landmark Agreement with Sunshine Lake Pharma to Pioneer Insulin Biosimilar Manufacturing in MENA
    • 12.3.6. Sanofi Launches New Long-Acting Insulin Drug in India
    • 12.3.7. California, Drugmaker Partner to Produce Affordable Insulin
    • 12.3.8. Novo Nordisk to Launch Once-a-Week Insulin Regime for Indian Patients
    • 12.3.9. ADOCIA Announces the Successful Phase 1 Study for BioChaperone Lispro with Partner Tonghua Dongbao
    • 12.3.10. Glenmark Launches Type 2 Diabetes and High Insulin Resistance Drug in India; Shares Jump
    • 12.3.11. Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
    • 12.3.12. Novo Nordisk Launches Unbranded Biologic of Tresiba Analog Insulin to Expand Affordability Options for Patients
    • 12.3.13. Optum, Sanofi Partner on Low Cost Insulin for the Uninsured

Companies Mentioned

  • 1. ADOCIA
  • 2. AstraZeneca PLC
  • 3. Baxter International, Inc.
  • 4. Biocon Limited
  • 5. Bioton S.A.
  • 6. CardioVends
  • 7. Eli Lilly and Company
  • 8. Eva Pharma
  • 9. GeneSys Biologics
  • 10. Glenmark Pharmaceuticals Ltd.
  • 11. Gulf Pharmaceutical Industries (Julphar)
  • 12. MannKind Corporation
  • 13. Merck & Co., Inc.
  • 14. MJ Biopharm Pvt. Ltd.
  • 15. Novartis AG
  • 16. Novo Nordisk A/S
  • 17. Oramed Pharmaceuticals Inc.
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 21. Viatris Inc.
  • 22. Wockhardt Limited
  • 23. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. INSULIN MARKET RESEARCH PROCESS
  • FIGURE 2. INSULIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INSULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INSULIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. INSULIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. INSULIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INSULIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INSULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INSULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INSULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INSULIN MARKET DYNAMICS
  • TABLE 7. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INSULIN MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INSULIN MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INSULIN MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INSULIN MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INSULIN MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INSULIN MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INSULIN MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INSULIN MARKET SIZE, BY TYPE I DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INSULIN MARKET SIZE, BY TYPE II DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. INSULIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. INSULIN MARKET, FPNV POSITIONING MATRIX, 2023